Tesamorelin is a modified 44-residue peptide. Its molecular description includes an N-terminal hexenoyl group and a C-terminal amide. Keep those groups with the sequence when comparing identity records.
Tesamorelin reference structure
The chemical-description section of the existing FDA source defines the 44-residue chain and an N-terminal hexenoyl group with a double bond at position 3. Its structural diagram also shows the C-terminal amide. The table transcribes this molecular reference rather than an unprinted structure from Novum’s report.FDA chemical description: tesamorelin, section 11 (March 2025) (opens in a new tab)
| Field | Reference or document detail |
|---|---|
| Name | Tesamorelin |
| Sequence with terminal groups | Hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2 |
| Residues | 44 |
| Peptide formula | C221H366N72O67S |
| Peptide molecular weight | 5135.9 Da, free-base equivalent |
| Acetate formula in the source | C221H366N72O67S · xC2H4O2, x approximately 7 |
| CAS number | Not verified for the supplied chemical form in the checked dossier |
Keep the modification and salt separate
The hexenoyl group is covalently attached to the N-terminal tyrosine. The acetate term describes the accompanying chemical form. These are separate fields: omitting the hexenoyl group changes the peptide description, while changing an acetate term changes the salt specification.FDA chemical description: tesamorelin, section 11 (March 2025) (opens in a new tab)
The molecular weight quoted above is for the peptide equivalent. It should not be relabelled as the total formula weight of every acetate composition. The source’s x term is retained rather than rounded into a fixed universal salt formula.FDA chemical description: tesamorelin, section 11 (March 2025) (opens in a new tab)
What is disclosed for the supplied sample?
Report MA-TES-0024, revision 01, identifies lot TES-24-AGH as a lyophilised 44-residue reference material and reports LC-HRMS identity matching. It does not print the full sequence, terminal modification or complete chemical form. Those details require the underlying reference specification.Tesamorelin 20 mg report: MA-TES-0024 (opens in a new tab)
Keep the literature structure, the sample’s declared material name and its batch document as linked records. Compare the report for the relevant vial size and lot; a shared compound name does not fill an undisclosed reference field.Tesamorelin 20 mg report: MA-TES-0024 (opens in a new tab)FDA chemical description: tesamorelin, section 11 (March 2025) (opens in a new tab)
Product and certificate checks
Sources and further detail
- Tesamorelin 20 mg report: MA-TES-0024 (opens in a new tab)
Supplied PDF re-read on 3 October 2026; available on request, as the product is not currently sold. Identity wording and document-specific results are transcribed; this is not independent authentication.
- FDA chemical description: tesamorelin, section 11 (March 2025) (opens in a new tab)
Existing dossier document, page 8: structural diagram, terminal groups, formula and peptide mass rechecked on 3 October 2026. Only chemical-description fields are used.
Revised 3 October 2026 using the existing source dossier and the specified primary identity records. Report values describe the linked samples. Products are for laboratory research use only.